Drug-eluting balloon catheter market seen reaching $2.92 billion by 2030

The Business Research Company says the global drug-eluting balloon catheter market will grow from $1.65 billion in 2025 to $2.92 billion by 2030, powered by rising cardiovascular and peripheral artery disease cases, more minimally invasive procedures and new coating technologies. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Drug-eluting balloon catheters are gaining traction as a stent-free option for treating coronary and peripheral artery disease. - The market’s projected rise to $2.92 billion by 2030 signals sustained demand for minimally invasive vascular therapies. - Rising cardiovascular and peripheral disease burdens are expanding the patient pool for these devices.

What happened: - The Business Research Company published a market forecast for the global drug-eluting balloon catheter sector on Aug. 5, 2026. - The report says the market will grow from $1.65 billion in 2025 to $1.86 billion in 2026. - The same forecast puts the market at $2.92 billion by 2030, implying an 11.9% compound annual growth rate from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the next several years.

The details: - Drug-eluting balloon catheters use a semi-compliant angioplasty balloon coated with an anti-proliferative drug. - The drug is released into the vessel wall when the balloon is inflated. - The device is designed to reduce restenosis, or re-narrowing of the artery, and minimize late thrombosis. - The technology leaves no permanent implant behind. - Growth in 2025 and 2026 was tied to higher coronary artery disease prevalence, wider use of percutaneous coronary interventions, better balloon catheter materials, acceptance of paclitaxel-coated devices and expansion of interventional cardiology centers. - Forecast growth is linked to demand for minimally invasive vascular therapies, wider use of sirolimus-based balloons, more peripheral vascular disease treatment, investment in next-generation catheter technology and a push to improve long-term outcomes. - Key trends include broader adoption of drug-coated balloon technology, more use in coronary and peripheral interventions, preference for stent-free treatment, improvements in drug coating methods and stronger efforts to prevent restenosis. - The report’s geographic coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also highlighted report features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, hotspot infographics and updated graphics and tables. - The report offers a free sample. - The full report is also available.

Between the lines: - The forecast points to a shift toward devices that deliver drugs locally while avoiding permanent implants. - The regional outlook suggests mature demand in North America and faster adoption opportunities in Asia-Pacific as healthcare access expands. - The report also reflects broader industry interest in coating chemistry and device design as competitive differentiators.

What's next: - The market is expected to keep expanding as hospitals and cardiology centers adopt more minimally invasive vascular treatment options. - Drug-eluting balloon technology will likely keep advancing as manufacturers pursue better coatings and broader coronary and peripheral indications. - The Business Research Company plans to keep updating its market report package with dashboards, graphics and trend analysis.